Milk and Cancer: What the Research Actually Shows

Few nutrition questions generate more anxiety than the link between dairy and cancer. Anti-dairy advocates cite IGF-1 and saturated fat. Dairy industry groups cite calcium and protective colon data. Both sides selectively emphasize evidence that fits their case. The actual picture, assembled from the world's largest cohort studies and supported by plausible biological mechanisms, is considerably more specific: dairy appears to meaningfully reduce risk of colorectal cancer, and it appears to modestly increase risk of prostate cancer at high intake levels. These effects are not contradictions. They reflect the fact that cancer is not one disease, and dairy is not one substance.

The UK Biobank: 500,000 People and a Decade of Follow-Up

The most comprehensive single analysis of dairy and cancer to date is a 2022 study published in BMC Medicine by Keren Papier and colleagues at the University of Oxford. The study drew on the UK Biobank, a prospective cohort of approximately 542,000 adults recruited between 2006 and 2010 and followed through cancer registry linkage into the early 2020s. At this scale, the study had statistical power to detect associations for more than 20 individual cancer types, not just the broad categories most smaller studies could examine.

The findings were striking in their specificity. Higher milk intake was associated with a statistically significant lower risk of colorectal cancer. Each 200ml daily increment of milk consumption was associated with approximately a 14% lower risk of colorectal cancer. Given that colorectal cancer is the third most diagnosed cancer globally, with around 1.9 million new cases in 2020 according to GLOBOCAN data, this is not a trivial finding. The protective association was not seen with cheese or yogurt to the same degree, suggesting the mechanism may relate specifically to milk's calcium content or its particular protein composition, rather than to dairy fat or fermentation products.

On the prostate cancer side, the Biobank data showed a 7% higher risk of prostate cancer per 200ml daily milk increment. This is a more modest association than some earlier studies suggested, and it remained after adjusting for body mass index, smoking, physical activity, and socioeconomic factors. The prostate cancer signal appeared more clearly for total dairy than for any individual dairy product.

The Colorectal Cancer Case: A Strong Protective Signal

The protective relationship between dairy and colorectal cancer has been one of the most replicated findings in nutritional epidemiology. The 2018 World Cancer Research Fund Continuous Update Project, which conducted a systematic review and dose-response meta-analysis covering more than 80 prospective studies, concluded that dairy products are a probable cause of decreased risk of colorectal cancer, representing one of the strongest dietary protective associations in the evidence base. The report estimated a 13% decrease in risk per 400g per day increase in dairy consumption.

Several mechanisms explain this plausibly. Calcium binds to bile acids and free fatty acids in the colon, forming insoluble complexes that reduce their contact with the colonic epithelium and suppress their ability to promote cell proliferation. In cell culture and animal studies, calcium at physiologically relevant concentrations induces differentiation and apoptosis in colonic epithelial cells. A randomized controlled trial by Bolland and colleagues at the University of Auckland, published in the American Journal of Clinical Nutrition in 2011, found that calcium supplementation reduced recurrence of colorectal adenomas, the precursor lesions to most colorectal cancers. Dairy also provides substantial amounts of vitamin D, which independently has anti-proliferative effects on colorectal tissue, and lactoferrin, a whey protein shown in animal studies to inhibit intestinal tumor development.

The Prostate Cancer Debate: IGF-1 and Hormones

The proposed mechanism linking dairy to elevated prostate cancer risk centers on insulin-like growth factor 1, known as IGF-1. Dairy protein, particularly whey, stimulates hepatic IGF-1 production. IGF-1 is a potent mitogen, meaning it promotes cell division. Prostate cancer cells, like most cancers, require growth signals to proliferate, and elevated circulating IGF-1 provides one. A 2001 meta-analysis in the British Journal of Cancer by Chan and colleagues found that men in the highest quintile of IGF-1 had more than twice the risk of advanced prostate cancer compared with those in the lowest quintile.

However, the story is complicated by the fact that IGF-1 is stimulated by protein intake generally, not specifically by dairy protein, and by the fact that the association between dairy and prostate cancer in large cohort studies is modest and inconsistent. The 2014 Health Professionals Follow-Up Study, covering 47,000 American men followed over 28 years, found that high dairy consumers had a 12% higher risk of total prostate cancer compared with low consumers, but no statistically significant increase in high-grade or fatal prostate cancer, which is what matters clinically. The UK Biobank finding of 7% per 200ml increment aligns with this: a real but modest signal, concentrated in low-grade disease.

Dairy also contains trace amounts of bovine estrogens and progesterone, which has fueled concern that hormone-sensitive cancers might be influenced by dairy consumption. A 2020 review in the Journal of Steroid Biochemistry and Molecular Biology by Malekinejad and colleagues found that commercially available milk contains measurable estrogen metabolites, but the quantities are orders of magnitude below the threshold required to produce systemic hormonal effects in adults. The endogenous estrogen produced by human fat tissue vastly exceeds any dairy-derived exposure.

WHO IARC Classification: Context Matters

The International Agency for Research on Cancer, the cancer research arm of the World Health Organization, has not classified dairy products as Group 1 (carcinogenic to humans) or Group 2A (probably carcinogenic). Red processed meat occupies Group 1. Red unprocessed meat is Group 2A. Dairy does not appear in IARC's classified lists as a carcinogen. This classification is not evidence that dairy is risk-free for all cancer types, but it is important context for headlines suggesting that drinking milk causes cancer.

IARC classifications are based on the strength of evidence that an agent can cause cancer under some circumstances, not on the magnitude of risk at typical exposure levels. An agent can be classified as Group 1 while posing a smaller absolute risk than many unclassified agents. Conversely, the absence of a classification does not mean an absence of risk. The classification system is a hazard identification tool, not a risk quantification tool, and is frequently misrepresented in popular media coverage.

The Dose Question: How Much Dairy Matters

The dose-response patterns in the literature suggest that moderate dairy consumption, in the range of 1 to 2 servings per day, carries neither the protective colorectal benefits seen at higher intakes nor the possible prostate risk signal seen at high intakes. The WCRF dose-response meta-analysis found the colorectal protective effect beginning to appear meaningfully above 400g daily, which represents roughly two large glasses of milk. The prostate cancer associations in most studies emerge most clearly in the highest consumption quartiles, typically above 600g of dairy per day, an amount that exceeds what most people consume.

For practical guidance, the current World Cancer Research Fund recommendations advise that dairy can be consumed as part of a healthy diet without specific restriction for cancer risk, while noting the colorectal protective evidence as sufficiently strong to consider dairy a beneficial food for colon health. Men with a family history of prostate cancer or those who consume very high quantities of dairy may wish to discuss their intake with a physician, but the absolute increase in risk at moderate intake levels is small enough that restriction is not universally recommended.

What the Evidence Does Not Support

The evidence does not support several common claims made in both pro- and anti-dairy discourse. It does not support the claim that dairy causes breast cancer. The UK Biobank found no significant association, and a 2019 meta-analysis in the European Journal of Nutrition covering 27 prospective studies found null or slightly protective associations between dairy and breast cancer. It does not support the claim that dairy causes bladder, kidney, or liver cancer at typical intake levels. And it does not support the claim that eliminating dairy will meaningfully reduce colorectal cancer risk. The evidence runs in the opposite direction.

The relationship between diet and cancer is rarely a simple on-off switch. It is shaped by genetic susceptibility, the rest of the diet, body weight, physical activity, and environmental exposures. Dairy's relationship with cancer follows this complexity. Two specific signals, one protective and one cautionary, emerge from the best available data. The rest is noise amplified by advocates on both sides who have reasons to simplify a complicated story.

Related: Dairy and Cardiovascular Health: What 130,000 People Taught Us | Dairy and the Gut Microbiome